## VTR: Ventas, Inc. - XLRE: Real Estate

### Executive Summary

No thesis match: MRS_20 2.2% below STRENGTH zone (4.0-10.0%); PEG 1.74 fails VALUE criteria (<1.0); RSI 74 overbought. Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS), overbought RSI (74).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($78.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Ventas Inc stock hits all-time high of 80.53 USD By Investing.com**
- Source: Investing.com Australia | 20251129T015600 | Bullish | Relevance: 99%
- Ventas Inc. stock reached an all-time high of $80.53, marking a 27.77% increase over the past year and a 38.96% year-to-date return. The healthcare REIT has a market capitalization of approximately $38 billion and maintains a consistent 2.4% dividend yield, having paid dividends for 27 consecutive years. Despite an InvestingPro analysis suggesting overvaluation, the company recently surpassed Q3 2025 earnings expectations, received a raised price target from Cantor Fitzgerald to $85, and announced the upcoming retirement of EVP Peter J. Bulgarelli.

**2. Why Is Ventas (VTR) Up 7.7% Since Last Earnings Report?**
- Source: www.sharewise.com | 20251129T023649 | Bullish | Relevance: 98%
- Ventas (VTR) shares have risen 7.7% since its last earnings report, outperforming the S&P 500. The company's Q3 2025 normalized FFO and revenues surpassed estimates, driven by strong performance in its SHOP and OM&R portfolios. Ventas has also increased its 2025 normalized FFO per share guidance.

**3. What Ventas (VTR)'s Raised 2025 Guidance and Senior Housing Expansion Mean For Shareholders**
- Source: Simply Wall Street | 20251129T235138 | Bullish | Relevance: 98%
- Ventas reported strong third-quarter 2025 results, beating FFO estimates and raising its 2025 guidance for both FFO and senior housing investment volume to US$2.5 billion. This expansion in senior housing, coupled with low short interest and positive analyst views, suggests market confidence in Ventas's strategy to benefit from aging demographics. The article highlights the importance of successful execution of these acquisitions for future earnings growth and distributions.

**4. What Ventas (VTR)'s Raised 2025 Guidance and Senior Housing Expansion Mean For Shareholders**
- Source: Simply Wall Street | 20251129T233636 | Bullish | Relevance: 98%
- Ventas (VTR) reported strong Q3 2025 results, beating estimates with 88 cents normalized FFO per share and raising its 2025 guidance, including investment volume in senior housing to US$2.5 billion. The company's focus on senior housing, supported by aging demographics and disciplined acquisitions, drives its investment narrative. Analysts remain positive, and forecasts project significant revenue and earnings growth, leading to an $82.95 fair value.

**5. (VTR) Movement as an Input in Quant Signal Sets**
- Source: Stock Traders Daily | 20251201T174200 | Bullish | Relevance: 98%
- This article from Stock Traders Daily analyzes Ventas Inc. (NYSE: VTR) by leveraging AI models to generate three distinct trading strategies based on different risk profiles and holding periods. Key findings indicate strong sentiment supporting an overweight bias, with specific entry, target, and stop-loss zones provided for position, momentum breakout, and risk hedging strategies. The analysis highlights elevated downside risk due to a lack of additional long-term support signals.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Keybanc | $85 | $70 | +21% |
| 2025-11-25 | Wells Fargo | $88 | $80 | +10% |
| 2025-11-13 | Scotiabank | $80 | $74 | +8% |
| 2025-11-11 | Citigroup | $88 | $80 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Keybanc | main | Overweight |
| 2025-11-25 | Wells Fargo | main | Overweight |
| 2025-11-13 | Scotiabank | main | Sector Perform |
| 2025-11-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 17 ($4.24M) |
| Sells | 14 ($23.22M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 15.7% (+2.5%)
- JPMORGAN CHASE & CO: 12.7% (+102.6%)
- Blackrock Inc.: 11.1% (+2.6%)
- State Street Corpora: 6.2% (+3.3%)
- FMR, LLC: 5.7% (+12.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $23M sold (14 transactions in 90 days).
3. Overbought RSI (74) with bearish MACD signals exhaustion.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.74 elevated, pricing in significant growth expectations. Analyst sentiment positive (4 raises, avg +12%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $36.5B |
| Beta | 0.79 |
| 52W Range | $56.68 - $81.89 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.74 |
| Forward P/E | 142.3 |
| Current P/E | 297.7 |
| YoY Growth | 109.3% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 4.5% to 2.2% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.8pp (needs >4.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. AM_20 at 3.3% shows strong absolute momentum above own 20MA. Outperforming sector by 3.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 74, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.16% (CS: 74) | Neutral |
| RSI_14 | 74.3 | Overbought |
| MACD Histogram | -0.01 | Bearish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.103x | Above |
| vs SMA200 | 1.181x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.39
- **Stop Loss:** $78.07 (2.9% risk)
- **Target:** $82.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 215
- **Position Value:** $17,283.85
- **Portfolio %:** 17.28%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-11 (Est: $0.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.05 | $0.12 | +141.9% |
| 2025Q2 | $0.14 | $0.15 | +10.4% |
| 2025Q1 | $0.07 | $0.10 | +35.8% |
| 2024Q4 | $0.05 | $0.13 | +156.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*